Transformative Biotech said it has developed extraction-free PCR chemistry for point-of-care testing, removing the bottleneck of nucleic acid extraction from sample workflows. The company’s patented buffer chemistry is described as stabilizing nucleic acids for room-temperature storage and enabling mail-in processing or downstream lab testing after a home collection. Transformative said the technology was originally developed at the University of Colorado Boulder and scaled during the pandemic, with the prior Summit Biolabs operation testing nearly 600,000 SARS-CoV-2 samples. The company is now building a handheld testing device called @Anywhere designed for smartphone-driven workflows. If translation holds, extraction-free PCR could reduce time, cost, and failure points in molecular diagnostics—especially for scalable decentralized testing models.